Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis

Secondary analysis of a randomized clinical trial

Niloy Jewel Samadder, Scott K. Kuwada, Kenneth M. Boucher, Kathryn Byrne, Priyanka Kanth, Wade Samowitz, David Jones, Sean V. Tavtigian, Michelle Westover, Therese Berry, Kory Jasperson, Lisa Pappas, Laurel Smith, Danielle Sample, Randall W. Burt, Deborah W. Neklason

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

IMPORTANCE Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. OBJECTIVE To evaluate effect of sulindac and erlotinib on colorectal adenoma regression in patients with FAP. DESIGN, SETTING, AND PARTICIPANTS Prespecified secondary analysis for colorectal adenoma regression was carried out using data from a double-blind, randomized, placebo-controlled trial, enrolling 92 patients with FAP, conducted from July 2010 to June 2014 in Salt Lake City, Utah. INTERVENTIONS Patients were randomized to sulindac, 150 mg twice daily, and erlotinib, 75 mg daily (n = 46), vs placebo (n = 46) for 6 months. MAIN OUTCOMES AND MEASUREMENTS The total number of polyps in the intact colorectum, ileal pouch anal anastomosis, or ileo-rectum were recorded at baseline and 6 months. The primary outcomes were change in total colorectal polyp count and percentage change in colorectal polyps, following 6 months of treatment. RESULTS Eighty-two randomized patients (mean [SD] age, 40 [13] years; 49 [60%] women) had colorectal polyp count data available for this secondary analysis: 22 with intact colon, 44 with ileal pouch anal anastomosis and 16 with ileo-rectal anastomosis; 41 patients received sulindac/erlotinib and 41 placebo. The total colorectal polyp count was significantly different between the placebo and sulindac-erlotinib group at 6 months in patients with net percentage change of 69.4% in those with an intact colorectum compared with placebo (95% CI, 28.8%-109.2%; P = .009). CONCLUSION AND RELEVANCE In this double-blind, placebo-controlled, randomized trial we showed that combination treatment with sulindac and erlotinib compared with placebo resulted in significantly lower colorectal polyp burden after 6 months of treatment. There was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum.

Original languageEnglish (US)
Pages (from-to)671-677
Number of pages7
JournalJAMA oncology
Volume4
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Sulindac
Adenomatous Polyposis Coli
Polyps
Randomized Controlled Trials
Placebos
Neoplasms
Colonic Pouches
Rectum
Adenoma
Erlotinib Hydrochloride
Colorectal Neoplasms
Colon
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis : Secondary analysis of a randomized clinical trial. / Samadder, Niloy Jewel; Kuwada, Scott K.; Boucher, Kenneth M.; Byrne, Kathryn; Kanth, Priyanka; Samowitz, Wade; Jones, David; Tavtigian, Sean V.; Westover, Michelle; Berry, Therese; Jasperson, Kory; Pappas, Lisa; Smith, Laurel; Sample, Danielle; Burt, Randall W.; Neklason, Deborah W.

In: JAMA oncology, Vol. 4, No. 5, 01.05.2018, p. 671-677.

Research output: Contribution to journalArticle

Samadder, NJ, Kuwada, SK, Boucher, KM, Byrne, K, Kanth, P, Samowitz, W, Jones, D, Tavtigian, SV, Westover, M, Berry, T, Jasperson, K, Pappas, L, Smith, L, Sample, D, Burt, RW & Neklason, DW 2018, 'Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: Secondary analysis of a randomized clinical trial', JAMA oncology, vol. 4, no. 5, pp. 671-677. https://doi.org/10.1001/jamaoncol.2017.5431
Samadder, Niloy Jewel ; Kuwada, Scott K. ; Boucher, Kenneth M. ; Byrne, Kathryn ; Kanth, Priyanka ; Samowitz, Wade ; Jones, David ; Tavtigian, Sean V. ; Westover, Michelle ; Berry, Therese ; Jasperson, Kory ; Pappas, Lisa ; Smith, Laurel ; Sample, Danielle ; Burt, Randall W. ; Neklason, Deborah W. / Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis : Secondary analysis of a randomized clinical trial. In: JAMA oncology. 2018 ; Vol. 4, No. 5. pp. 671-677.
@article{bdfd74135bfd4a1f935acd646808aed7,
title = "Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: Secondary analysis of a randomized clinical trial",
abstract = "IMPORTANCE Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71{\%} reduction in duodenal polyp burden in a phase 2 trial. OBJECTIVE To evaluate effect of sulindac and erlotinib on colorectal adenoma regression in patients with FAP. DESIGN, SETTING, AND PARTICIPANTS Prespecified secondary analysis for colorectal adenoma regression was carried out using data from a double-blind, randomized, placebo-controlled trial, enrolling 92 patients with FAP, conducted from July 2010 to June 2014 in Salt Lake City, Utah. INTERVENTIONS Patients were randomized to sulindac, 150 mg twice daily, and erlotinib, 75 mg daily (n = 46), vs placebo (n = 46) for 6 months. MAIN OUTCOMES AND MEASUREMENTS The total number of polyps in the intact colorectum, ileal pouch anal anastomosis, or ileo-rectum were recorded at baseline and 6 months. The primary outcomes were change in total colorectal polyp count and percentage change in colorectal polyps, following 6 months of treatment. RESULTS Eighty-two randomized patients (mean [SD] age, 40 [13] years; 49 [60{\%}] women) had colorectal polyp count data available for this secondary analysis: 22 with intact colon, 44 with ileal pouch anal anastomosis and 16 with ileo-rectal anastomosis; 41 patients received sulindac/erlotinib and 41 placebo. The total colorectal polyp count was significantly different between the placebo and sulindac-erlotinib group at 6 months in patients with net percentage change of 69.4{\%} in those with an intact colorectum compared with placebo (95{\%} CI, 28.8{\%}-109.2{\%}; P = .009). CONCLUSION AND RELEVANCE In this double-blind, placebo-controlled, randomized trial we showed that combination treatment with sulindac and erlotinib compared with placebo resulted in significantly lower colorectal polyp burden after 6 months of treatment. There was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum.",
author = "Samadder, {Niloy Jewel} and Kuwada, {Scott K.} and Boucher, {Kenneth M.} and Kathryn Byrne and Priyanka Kanth and Wade Samowitz and David Jones and Tavtigian, {Sean V.} and Michelle Westover and Therese Berry and Kory Jasperson and Lisa Pappas and Laurel Smith and Danielle Sample and Burt, {Randall W.} and Neklason, {Deborah W.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1001/jamaoncol.2017.5431",
language = "English (US)",
volume = "4",
pages = "671--677",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis

T2 - Secondary analysis of a randomized clinical trial

AU - Samadder, Niloy Jewel

AU - Kuwada, Scott K.

AU - Boucher, Kenneth M.

AU - Byrne, Kathryn

AU - Kanth, Priyanka

AU - Samowitz, Wade

AU - Jones, David

AU - Tavtigian, Sean V.

AU - Westover, Michelle

AU - Berry, Therese

AU - Jasperson, Kory

AU - Pappas, Lisa

AU - Smith, Laurel

AU - Sample, Danielle

AU - Burt, Randall W.

AU - Neklason, Deborah W.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - IMPORTANCE Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. OBJECTIVE To evaluate effect of sulindac and erlotinib on colorectal adenoma regression in patients with FAP. DESIGN, SETTING, AND PARTICIPANTS Prespecified secondary analysis for colorectal adenoma regression was carried out using data from a double-blind, randomized, placebo-controlled trial, enrolling 92 patients with FAP, conducted from July 2010 to June 2014 in Salt Lake City, Utah. INTERVENTIONS Patients were randomized to sulindac, 150 mg twice daily, and erlotinib, 75 mg daily (n = 46), vs placebo (n = 46) for 6 months. MAIN OUTCOMES AND MEASUREMENTS The total number of polyps in the intact colorectum, ileal pouch anal anastomosis, or ileo-rectum were recorded at baseline and 6 months. The primary outcomes were change in total colorectal polyp count and percentage change in colorectal polyps, following 6 months of treatment. RESULTS Eighty-two randomized patients (mean [SD] age, 40 [13] years; 49 [60%] women) had colorectal polyp count data available for this secondary analysis: 22 with intact colon, 44 with ileal pouch anal anastomosis and 16 with ileo-rectal anastomosis; 41 patients received sulindac/erlotinib and 41 placebo. The total colorectal polyp count was significantly different between the placebo and sulindac-erlotinib group at 6 months in patients with net percentage change of 69.4% in those with an intact colorectum compared with placebo (95% CI, 28.8%-109.2%; P = .009). CONCLUSION AND RELEVANCE In this double-blind, placebo-controlled, randomized trial we showed that combination treatment with sulindac and erlotinib compared with placebo resulted in significantly lower colorectal polyp burden after 6 months of treatment. There was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum.

AB - IMPORTANCE Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. OBJECTIVE To evaluate effect of sulindac and erlotinib on colorectal adenoma regression in patients with FAP. DESIGN, SETTING, AND PARTICIPANTS Prespecified secondary analysis for colorectal adenoma regression was carried out using data from a double-blind, randomized, placebo-controlled trial, enrolling 92 patients with FAP, conducted from July 2010 to June 2014 in Salt Lake City, Utah. INTERVENTIONS Patients were randomized to sulindac, 150 mg twice daily, and erlotinib, 75 mg daily (n = 46), vs placebo (n = 46) for 6 months. MAIN OUTCOMES AND MEASUREMENTS The total number of polyps in the intact colorectum, ileal pouch anal anastomosis, or ileo-rectum were recorded at baseline and 6 months. The primary outcomes were change in total colorectal polyp count and percentage change in colorectal polyps, following 6 months of treatment. RESULTS Eighty-two randomized patients (mean [SD] age, 40 [13] years; 49 [60%] women) had colorectal polyp count data available for this secondary analysis: 22 with intact colon, 44 with ileal pouch anal anastomosis and 16 with ileo-rectal anastomosis; 41 patients received sulindac/erlotinib and 41 placebo. The total colorectal polyp count was significantly different between the placebo and sulindac-erlotinib group at 6 months in patients with net percentage change of 69.4% in those with an intact colorectum compared with placebo (95% CI, 28.8%-109.2%; P = .009). CONCLUSION AND RELEVANCE In this double-blind, placebo-controlled, randomized trial we showed that combination treatment with sulindac and erlotinib compared with placebo resulted in significantly lower colorectal polyp burden after 6 months of treatment. There was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum.

UR - http://www.scopus.com/inward/record.url?scp=85047464425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047464425&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2017.5431

DO - 10.1001/jamaoncol.2017.5431

M3 - Article

VL - 4

SP - 671

EP - 677

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 5

ER -